Principal Financial Group Inc Seres Therapeutics, Inc. Transaction History

Principal Financial Group Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$0.56 - $1.19 $9,167 - $19,480	-16,370 Reduced 60.43%	10,718 $7,000
Q1 2024 Apr 29, 2024	SELL	$0.75 - $1.56 $25,932 - $53,938	-34,576 Reduced 56.07%	27,088 $20,000
Q4 2023 Feb 07, 2024	BUY	$0.93 - $2.15 $7,180 - $16,600	7,721 Added 14.31%	61,664 $86,000
Q3 2023 Nov 02, 2023	BUY	$2.33 - $5.07 $20,359 - $44,301	8,738 Added 19.33%	53,943 $128,000
Q2 2023 Aug 07, 2023	BUY	$4.67 - $6.55 $37,420 - $52,485	8,013 Added 21.54%	45,205 $216,000
Q1 2023 May 09, 2023	SELL	$4.95 - $6.09 $22,081 - $27,167	-4,461 Reduced 10.71%	37,192 $210,000
Q4 2022 Feb 09, 2023	BUY	$5.09 - $9.05 $105,724 - $187,977	20,771 Added 99.47%	41,653 $233,000
Q3 2022 Nov 09, 2022	SELL	$3.5 - $7.2 $1,263 - $2,599	-361 Reduced 1.7%	20,882 $134,000
Q2 2022 Aug 10, 2022	SELL	$2.7 - $7.62 $4,897 - $13,822	-1,814 Reduced 7.87%	21,243 $73,000
Q1 2022 May 09, 2022	BUY	$6.3 - $8.84 $1,984 - $2,784	315 Added 1.39%	23,057 $164,000
Q4 2021 Feb 09, 2022	SELL	$6.02 - $11.43 $62,595 - $118,849	-10,398 Reduced 31.38%	22,742 $189,000
Q3 2021 Nov 09, 2021	SELL	$5.46 - $22.6 $133,109 - $550,965	-24,379 Reduced 42.38%	33,140 $230,000
Q2 2021 Aug 10, 2021	SELL	$18.46 - $24.36 $19,641 - $25,919	-1,064 Reduced 1.82%	57,519 $1.37 Million
Q1 2021 May 10, 2021	BUY	$17.66 - $28.92 $461,967 - $756,518	26,159 Added 80.68%	58,583 $1.21 Million
Q4 2020 Feb 08, 2021	BUY	$23.25 - $37.73 $567,579 - $921,064	24,412 Added 304.69%	32,424 $795,000
Q3 2020 Nov 06, 2020	BUY	$3.74 - $28.74 $29,964 - $230,264	8,012 New	8,012 $226,000

46.7M

119K

466K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $102M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.